Pinned Tweet
Are you still worried about stock selection? Join now for real-time guidance!
Click the link to quickly join:
wa.me/19295846644?text=Stock
Or visit my WhatsApp profile, add me as a contact, and text the word "Stock". I will get back to you as soon as possible.
We're building a community focused on:
market insights
Equity research
key points
trading strategy
Private WhatsApp group – space is limited.
Today is your last chance to take advantage of this opportunity, act now!
Follow me or send a private message and I'll give you the details to join the group.
#stock
#stockmarket
#AIStocks
#TSLA
$RMIX +23.97%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#RMIX
#Stocks
#QQQ
#AIStocks
#NVDA
97
Want to get a head start on stock market insights and snap up stocks poised for a major surge?
Click this link:
wa.me/13476167808?text=Stock
Or, click the link in my profile to add me on WhatsApp.
Once connected, I’ll share the same stock insights with you that I post in my private group.
I only share full stock details—including specific entry ranges, clear stop-loss levels, and real-time exit prices—exclusively with members of my private group.
If you want to stay ahead of market trends, come join us!
#Stocks
#QQQ
#AIStocks
#TSLA
$RMIX +23.97%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#RMIX
#Stocks
#QQQ
#AIStocks
#NVDA
65
$RMIX +23.97%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#RMIX
#Stocks
#QQQ
#AIStocks
#NVDA
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $R***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
$ZLAB
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Global biopharma. Positive Phase 1 data for ZL-1503 (long-acting IL-13/IL-31 bispecific for atopic dermatitis); KarXT and VYVGART Hytrulo first-time inclusion on China’s 2026 NRDL (access expansion). Multiple 2027 pipeline catalysts (including zoci in SCLC).
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#ZLAB
#Stocks
#StockMarket
#AIStocks
$ZLAB
Zai Lab is a biopharmaceutical company with commercial products in China and a global clinical pipeline, including the zoci program in oncology.
Q3 total revenue was $108.2 million, down about 7% year over year but up slightly sequentially. Net product revenue was $107.6 million. Net loss was $46.1 million. Cash was approximately $660 million at quarter-end (prior to a subsequent $250 million private placement). The company is advancing multiple registrational studies for zoci, with key readouts and a potential first U.S. BLA submission targeted for 2027. Commercial trends in China were mixed amid pricing and competitive dynamics on certain products.
Here’s the key distinction: current revenue is stable to slightly down while the company invests in a late-stage global pipeline with multiple 2027 catalysts.
What could move $ZLAB higher?
Positive zoci clinical data and progression toward BLA
Revenue returns to growth in 2027 as patient access expands
Cash runway remains supportive through key milestones
Additional pipeline progress
What could go wrong?
Clinical timelines slip or data disappoint
Continued pressure on commercial products in China
Higher R&D or SG&A spending
My take: $ZLAB is transitioning from a China commercial base toward a more global late-stage pipeline. Delivery on the 2027 clinical and regulatory milestones will be the main driver. Watch zoci study updates, revenue trends, and cash position.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#ZLAB #Biotech #Oncology #Earnings
101
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $R***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
$ZLAB
Zai Lab is a biopharmaceutical company with commercial products in China and a global clinical pipeline, including the zoci program in oncology.
Q3 total revenue was $108.2 million, down about 7% year over year but up slightly sequentially. Net product revenue was $107.6 million. Net loss was $46.1 million. Cash was approximately $660 million at quarter-end (prior to a subsequent $250 million private placement). The company is advancing multiple registrational studies for zoci, with key readouts and a potential first U.S. BLA submission targeted for 2027. Commercial trends in China were mixed amid pricing and competitive dynamics on certain products.
Here’s the key distinction: current revenue is stable to slightly down while the company invests in a late-stage global pipeline with multiple 2027 catalysts.
What could move $ZLAB higher?
Positive zoci clinical data and progression toward BLA
Revenue returns to growth in 2027 as patient access expands
Cash runway remains supportive through key milestones
Additional pipeline progress
What could go wrong?
Clinical timelines slip or data disappoint
Continued pressure on commercial products in China
Higher R&D or SG&A spending
My take: $ZLAB is transitioning from a China commercial base toward a more global late-stage pipeline. Delivery on the 2027 clinical and regulatory milestones will be the main driver. Watch zoci study updates, revenue trends, and cash position.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#ZLAB #Biotech #Oncology #Earnings
$ZLAB
Zai Lab is a biopharmaceutical company with commercial products in China and a global clinical pipeline, including the zoci program in oncology.
Q3 total revenue was $108.2 million, down about 7% year over year but up slightly sequentially. Net product revenue was $107.6 million. Net loss was $46.1 million. Cash was approximately $660 million at quarter-end (prior to a subsequent $250 million private placement). The company is advancing multiple registrational studies for zoci, with key readouts and a potential first U.S. BLA submission targeted for 2027. Commercial trends in China were mixed amid pricing and competitive dynamics on certain products.
Here’s the key distinction: current revenue is stable to slightly down while the company invests in a late-stage global pipeline with multiple 2027 catalysts.
What could move $ZLAB higher?
Positive zoci clinical data and progression toward BLA
Revenue returns to growth in 2027 as patient access expands
Cash runway remains supportive through key milestones
Additional pipeline progress
What could go wrong?
Clinical timelines slip or data disappoint
Continued pressure on commercial products in China
Higher R&D or SG&A spending
My take: $ZLAB is transitioning from a China commercial base toward a more global late-stage pipeline. Delivery on the 2027 clinical and regulatory milestones will be the main driver. Watch zoci study updates, revenue trends, and cash position.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#ZLAB #Biotech #Oncology #Earnings
Nvidia beat and futures are green, but I’m still watching for the fade. Influenced by the strong numbers and the Anthropic IPO, the AI infrastructure sector is the one worth watching for follow-through or a fade. I’ve been adding a bit on strength and organizing exposure. My take? Demand is real, but leadership uncertainty can still cap the move.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#ContrarianView #NvidiaEarnings #AIDemand #DipWatch
132
$ELA +19.41%
Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Q3 diluted EPS $0.15 (beat), operating income and gross margin up despite lower revenue. Re-commerce (reuse/recycle) model showing margin resilience. Analysts cut targets but kept Buy ratings on the profitability focus.
I will share my unique market insights with you. I will share similar high-potential stocks with you daily.
#ELA
#Stocks
#StockMarket
#StockTrading
#AIStocks
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $E***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
$ELA +15.75%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#ELA
#Stocks
#QQQ
#AIStocks
#NVDA
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $E***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
108
$SLDE +2.11%
My prediction of the uptrend was absolutely correct—we are currently in an uptrend.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Strong Q3 net income growth, raised full-year net income guidance to $500-520M, $1.50 special dividend, geographic expansion (Texas, California), and high ROE. Coastal property insurer with capital return and growth momentum.
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#SLDE
#Stocks
#StockMarket
#AIStocks
$SLDE
Slide Insurance is a coastal-focused property and casualty insurer specializing in homeowners and related coverage, primarily in Florida with expansion into other states.
Q3 gross written premiums were $506.6 million, up 9.3% year over year. Total revenue rose 35.9% to $361.1 million. Net income increased 24.5% to $138.2 million, or $1.09 diluted EPS. The combined ratio was 59.3% (accident-year ex-catastrophe around 54.4%). The company declared a $1.50 special dividend in addition to its regular quarterly dividend. It raised full-year 2026 gross written premium guidance to $1.90–1.95 billion and net income guidance to $500–520 million. Expansion into new states (including Texas) is underway.
Here’s the key distinction: strong premium growth and profitability continue even with catastrophe activity in the quarter, supported by underwriting discipline and geographic expansion.
What could move $SLDE higher?
Premium growth stays in the high single digits or better
Combined ratio remains disciplined
Full-year net income hits the raised guidance
Expansion outside Florida scales successfully
Capital returns continue
What could go wrong?
Higher-than-expected catastrophe losses
Reserve development turns unfavorable
Competition or rate pressure in key markets
Expansion costs weigh on results
My take: $SLDE is a high-ROE coastal specialty insurer delivering growth and capital returns. Catastrophe exposure remains the key variable. Watch quarterly premium trends, combined ratios, guidance updates, and any commentary on expansion markets.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#SLDE #Insurance #PropertyCasualty #Earnings
145
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $E***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
$SLDE
Slide Insurance is a coastal-focused property and casualty insurer specializing in homeowners and related coverage, primarily in Florida with expansion into other states.
Q3 gross written premiums were $506.6 million, up 9.3% year over year. Total revenue rose 35.9% to $361.1 million. Net income increased 24.5% to $138.2 million, or $1.09 diluted EPS. The combined ratio was 59.3% (accident-year ex-catastrophe around 54.4%). The company declared a $1.50 special dividend in addition to its regular quarterly dividend. It raised full-year 2026 gross written premium guidance to $1.90–1.95 billion and net income guidance to $500–520 million. Expansion into new states (including Texas) is underway.
Here’s the key distinction: strong premium growth and profitability continue even with catastrophe activity in the quarter, supported by underwriting discipline and geographic expansion.
What could move $SLDE higher?
Premium growth stays in the high single digits or better
Combined ratio remains disciplined
Full-year net income hits the raised guidance
Expansion outside Florida scales successfully
Capital returns continue
What could go wrong?
Higher-than-expected catastrophe losses
Reserve development turns unfavorable
Competition or rate pressure in key markets
Expansion costs weigh on results
My take: $SLDE is a high-ROE coastal specialty insurer delivering growth and capital returns. Catastrophe exposure remains the key variable. Watch quarterly premium trends, combined ratios, guidance updates, and any commentary on expansion markets.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#SLDE #Insurance #PropertyCasualty #Earnings
$SLDE
Slide Insurance is a coastal-focused property and casualty insurer specializing in homeowners and related coverage, primarily in Florida with expansion into other states.
Q3 gross written premiums were $506.6 million, up 9.3% year over year. Total revenue rose 35.9% to $361.1 million. Net income increased 24.5% to $138.2 million, or $1.09 diluted EPS. The combined ratio was 59.3% (accident-year ex-catastrophe around 54.4%). The company declared a $1.50 special dividend in addition to its regular quarterly dividend. It raised full-year 2026 gross written premium guidance to $1.90–1.95 billion and net income guidance to $500–520 million. Expansion into new states (including Texas) is underway.
Here’s the key distinction: strong premium growth and profitability continue even with catastrophe activity in the quarter, supported by underwriting discipline and geographic expansion.
What could move $SLDE higher?
Premium growth stays in the high single digits or better
Combined ratio remains disciplined
Full-year net income hits the raised guidance
Expansion outside Florida scales successfully
Capital returns continue
What could go wrong?
Higher-than-expected catastrophe losses
Reserve development turns unfavorable
Competition or rate pressure in key markets
Expansion costs weigh on results
My take: $SLDE is a high-ROE coastal specialty insurer delivering growth and capital returns. Catastrophe exposure remains the key variable. Watch quarterly premium trends, combined ratios, guidance updates, and any commentary on expansion markets.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#SLDE #Insurance #PropertyCasualty #Earnings
Been updating the watchlist and reorganizing ahead of Nvidia’s print. Influenced by the leadership change and tonight’s earnings, the AI infrastructure and semiconductor sector is the one worth paying the most attention to today. Futures are softer after yesterday’s drop. I’ve been selectively adding names while keeping size disciplined. My take is that the catalysts are real, so stay selective into the numbers.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#WatchlistUpdate #NvidiaEarnings #AIInfrastructure #PremarketCheck
112
$GMM +97.06%
Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Announced indirect investment in Anthropic (Claude) through a fund. Classic AI-adjacent hype — stock nearly tripled on the news. High-volume momentum play.
I will share my unique market insights with you. I will share similar high-potential stocks with you daily.
#GMM
#Stocks
#StockMarket
#StockTrading
#AIStocks
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $G***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
1
149
$GMM +115.69%
Many group members followed my latest trading advice and made substantial profits
Missed this opportunity? Don't worry!—Today is the last chance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Our community shares the following:
Individual stock trends
Key support and resistance levels
Various market catalysts
Short-term trading opportunities
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#GMM
#Stocks
#QQQ
#AIStocks
#NVDA
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $G***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
180
$IDYA +0.06%
My prediction of the uptrend was absolutely correct—we are currently in an uptrend.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Nominated IDE101 development candidate: first-in-class dual CDK inhibitor for CDKN2A-deficient tumors (~10-15% of solid tumors, ~70% pancreatic). Preclinical activity mono and combo (incl. with their PRMT5 IDE892 and RAS inhibitors). IND-enabling ongoing, IND target H1 2027. London R&D Day highlighting the program.
Sensory post: Watching a precision oncology name drop a new candidate aimed at one of the most common tumor suppressor losses in pancreatic cancer.American colloquial: IDEAYA just nominated a new first-in-class drug for CDKN2A loss. Big in pancreatic. They’re talking about it at their R&D day.
Private WhatsApp community—limited spots available.
Join us to stay up-to-date with market movements.
#PrecisionOncology #CDKN2A #IDE101 #PancreaticCancer #Biotech
$IDYA
IDEAYA Biosciences is a clinical-stage oncology company.
Q3 collaboration revenue was $10.2 million. Net loss was $125.7 million as R&D spending increased. Cash and investments totaled $1.15 billion, with runway expected into 2030. The company submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma under the RTOR program. Multiple other programs are advancing.
Here’s the distinction: this is a well-funded clinical-stage biotech where value is driven by pipeline milestones rather than current revenue.
What could move $IDYA higher?
Positive regulatory progress on the darovasertib NDA
Additional clinical data from other programs
New partnerships or expansions
Cash runway remains long
What could go wrong?
Clinical or regulatory setbacks
Higher-than-expected cash burn
Competitive oncology landscape
My take: $IDYA has a large cash balance supporting multiple oncology shots. Near-term catalysts are regulatory and clinical updates. Watch NDA progress, cash burn, and any data readouts.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#IDYA #Biotech #Oncology #Earnings
145
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $G***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
$IDYA
IDEAYA Biosciences is a clinical-stage oncology company.
Q3 collaboration revenue was $10.2 million. Net loss was $125.7 million as R&D spending increased. Cash and investments totaled $1.15 billion, with runway expected into 2030. The company submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma under the RTOR program. Multiple other programs are advancing.
Here’s the distinction: this is a well-funded clinical-stage biotech where value is driven by pipeline milestones rather than current revenue.
What could move $IDYA higher?
Positive regulatory progress on the darovasertib NDA
Additional clinical data from other programs
New partnerships or expansions
Cash runway remains long
What could go wrong?
Clinical or regulatory setbacks
Higher-than-expected cash burn
Competitive oncology landscape
My take: $IDYA has a large cash balance supporting multiple oncology shots. Near-term catalysts are regulatory and clinical updates. Watch NDA progress, cash burn, and any data readouts.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#IDYA #Biotech #Oncology #Earnings
$IDYA
IDEAYA Biosciences is a clinical-stage oncology company.
Q3 collaboration revenue was $10.2 million. Net loss was $125.7 million as R&D spending increased. Cash and investments totaled $1.15 billion, with runway expected into 2030. The company submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma under the RTOR program. Multiple other programs are advancing.
Here’s the distinction: this is a well-funded clinical-stage biotech where value is driven by pipeline milestones rather than current revenue.
What could move $IDYA higher?
Positive regulatory progress on the darovasertib NDA
Additional clinical data from other programs
New partnerships or expansions
Cash runway remains long
What could go wrong?
Clinical or regulatory setbacks
Higher-than-expected cash burn
Competitive oncology landscape
My take: $IDYA has a large cash balance supporting multiple oncology shots. Near-term catalysts are regulatory and clinical updates. Watch NDA progress, cash burn, and any data readouts.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#IDYA #Biotech #Oncology #Earnings
NQ futures off nearly 1%, ES down about 0.3%, Dow flat. Nvidia down ~2% premarket into tomorrow’s print. Influenced by the leadership change and earnings risk, the AI and semiconductor sector is the focus I’m tracking closely. I’ve been adding selective names and organizing the list. View: caution into the catalysts makes sense; broader market is holding better than pure tech.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
#FuturesData #NvidiaDown #SemiFocus #RiskOnOff
137
$CNVS +23.76%
Today's closing price confirms the accuracy of my previous predictions regarding this stock's performance.
If you are interested in joining, please click on my profile to add my WhatsApp number and send me a message. I will invite you.
Fiscal Q2 revenue +110% to $26M (acquisitions IndiCue + Giant Worldwide). EPS $0.11 (big beat), Adj. EBITDA positive $1.7M (third straight positive quarter). Reaffirmed FY27 guidance $115-120M revenue / $10-20M Adj. EBITDA. Technology/media services now >50% of revenue. Also picked up rights to next Jason Voorhees film.
I will share my unique market insights with you. I will share similar high-potential stocks with you daily.
#CNVS
#Stocks
#StockMarket
#StockTrading
#AIStocks
Do you want to get the latest stock market news first and buy stocks that are about to skyrocket?
In my private community, members receive complete trading strategies even before the market begins to fluctuate.
Today's Alert: $C***
Expected Intraday Volatility: 10%–40%
In the community, I will share:
Entry Range
Stop-Loss Level
Real-Time Sell Alerts
Daily Sharing of High-Quality Intraday Trading Opportunities.
I focus on complete trade execution and risk control.
Want to get the latest and most comprehensive information and accurate stock codes? Please like and follow me, or click the number on my profile to add me on WhatsApp and send me a message. I will invite you to join and send you stock information.
I will send you stock information.
#Stock
#QQQ
#StockMarket
#StockTrading
#AIStocks
1
128















